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A B S T R A C T   
Background: The PHQ-9 is a self-administered depression screening instrument. Little is known about its utility 
and accuracy in detecting depression in adults with dissociative seizures (DS). 
Objectives: Using the Mini – International Neuropsychiatric Interview as a reference, we evaluated the diagnostic 
accuracy of the PHQ-9 in adults with DS, and examined its convergent and discriminant validity and uniformity. 
Methods: Our sample comprised 368 people with DS who completed the pre-randomisation assessment of the 
CODES trial. The uniformity of the PHQ-9 was determined using factor analysis for categorical data. Optimal cut- 
offs were determined using the area under the curve (AUC), Youden Index, and diagnostic odds ratio (DOR). 
Convergent and discriminant validity were assessed against pre-randomisation measures. 
Results: Internal consistency of the PHQ-9 was high (α = 0.87). While the diagnostic odds ratio suggested that a 
cut-off of ≥10 had the best predictive performance (DOR = 14.7), specificity at this cut off was only 0.49. AUC 
(0.74) and Youden Index (0.48) suggested a ≥ 13 cut-off would yield an optimal sensitivity (0.81) and specificity 
(0.67) balance. However, a cut-off score of ≥20 would be required to match specificity resulting from a cut-off of 
≥13 in other medical conditions. We found good convergent and discriminant validity and one main factor for 
the PHQ-9. 
Conclusions: In terms of internal consistency and structure, our findings were consistent with previous validation 
studies but indicated that a higher cut-off would be required to identify DS patients with depression with similar 
specificity achieved with PHQ-9 screening in different clinical and non-clinical populations.   
1. Introduction 
Dissociative seizures (DS) superficially resemble epileptic seizures 
but are not caused by the abnormal electrical discharges in the brain. DS 
are interpreted as an experiential and behavioural dissociative response 
to arousal and perceived as non-volitional [1]. Together with epilepsy 
and syncope, dissociative seizures account for 90% of clinical pre-
sentations with transient loss of consciousness. The prevalence of DS in 
the general population has been estimated as 50/100.000 [2]. Depres-
sion is one of the commonest comorbid disorders in patients with 
dissociative seizures (DS) [3–5]. Prevalence rates of depression in adults 
with DS range from 21% to 60% and are higher than in the general 
population and patients with epilepsy [6]. Health-related quality of life 
(HRQoL) is lower in patients with DS compared to those with epilepsy 
[7] and closely correlated with depression [8]. A recent systematic re-
view found that depression correlated more closely with HRQoL than 
with seizure-related factors, and lower depression scores were the only 
determinant of higher HRQoL [9], suggesting that successful treatment 
of depression may improve clinical outcomes in patients with DS [10]. 
Unanswered questions remain about how to optimally identify 
clinically relevant depression, and what contribution self-report tools 
can make to this. A recent meta-analysis compared studies based on self- 
report methods and clinical diagnoses and highlighted clear disparities 
in the reported prevalence of depression in adults with DS depending on 
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the case ascertainment method [5]. There are a number of factors, which 
could adversely affect the accuracy of self-report measures of depression 
in this population; there is also the pragmatic issue of availability of 
expertise. For many patients, assessment by an experienced consultant 
neuropsychiatrist is simply not available and diagnostic support tools 
are a necessary part of service provision. Among other factors that may 
affect accuracy of assessment, psychological aspects of DS are often 
stigmatised [11,12], and patients may find it difficult to admit to 
negative emotions. Depressive symptoms may also present atypically in 
this population and, compared to patients with epilepsy, DS patients 
may be more likely to endorse somatic rather than affective symptoms of 
depression [5]. These characteristics and the high levels of somatic 
symptoms reported by many patients in addition to their DS could affect 
the specificity of screening tools for depression [13]. 
The Patient Health Questionnaire-9 (PHQ-9) [14] is a brief, self- 
administered tool that is widely used to screen for depressive symp-
toms in clinical and research settings. For instance, in the United 
Kingdom the PHQ-9 is not only employed by providers of “Improving 
Access to Psychological Therapies” (IAPT) to assess patients’ suitability 
for particular services but also as an outcome and performance measure 
of IAPT services. Although it has been widely used in clinical and non- 
clinical populations, current evidence regarding optimal PHQ-9 cut- 
offs for depression screening accuracy remains inconclusive. Due to the 
high specificity and sensitivity reported in the original validation study, 
a cut-off score of ≥10 has become the recommended threshold for the 
identification of individuals likely to have clinically significant depres-
sion [14]; however, inflexible adherence to a specific cut-off has been 
criticised by the same authors [15]. Two individual patient data meta- 
analyses across different patient populations have generated different 
values as optimal cut-offs: a PHQ-9 ≥ 10 [16], or PHQ-9 ≥ 14 [17]. 
To our knowledge, no study has yet sought to validate the use of the 
PHQ-9 and determine optimal cut-off scores in a DS population. Thus, its 
utility as a screening instrument and sensitive treatment outcome 
measure remains uncertain in this patient group. The primary aim of this 
study was, therefore, to measure the sensitivity and specificity of the 
PHQ-9 in detecting depression in patients with DS, using the Mini - In-
ternational Neuropsychiatric Interview (M.I.N⋅I.) [18] as a “gold stan-
dard” diagnostic reference. 
Previous studies indicate that the PHQ-9’s cognitive/affective (PHQ- 
9/CA), and somatic (PHQ-9/S) subscales may differentially contribute 
to depression screening accuracy in patients with epilepsy [19,20]. 
Therefore, secondary aims of our study included an examination of the 
uniformity of the PHQ-9 scale through exploratory and confirmatory 
factor analysis as well as an examination of the convergent and 




The patients who contributed self-report and interview data for this 
analysis were participating in the CODES trial, a multi-centre rando-
mised controlled trial (RCT) comparing the clinical and cost effective-
ness of Cognitive Behavioural Therapy (CBT) plus standardized medical 
care (SMC) and SMC alone in adults with DS. Patient data were captured 
at the point of recruitment into the intervention phase of this study 
between January 2015 and May 2017 (see previous publications for 
details of the trial and recruitment procedure) [21–24]. Inclusion and 
exclusion criteria are given in Supplementary Material 1. Written 
informed consent was obtained from all participants at each phase of the 
CODES study and ethical approval was granted by the NRES London- 
Camberwell St Giles Ethics Committee (13/LO/1595). 
2.2. Measures 
The Mini - International Neuropsychiatric Interview (M.I.N.I.; 
version 6) [18] was used. It is a structured interview for psychiatric 
diagnoses, based on DSM-IV criteria and the International Classification 
of Diseases-10 (ICD-10) [25]. It comprises 17 modules, each with 8–10 
questions, which measure the symptoms for common psychiatric dis-
orders including major depression. Its reliability and validity are well 
established [26]. Interviewers were postgraduate research assistants 
with different training and professional backgrounds. All interviewers 
had previous direct experience with patients and received a full day 
training to administer the M.I.N.I. in compliance with the administration 
procedures laid out in the M.I.N.I. manual. A similar approach to vali-
dating the PHQ-9 against the M.I.N.I. has previously been undertaken in 
patients with epilepsy [20]. The M.I.N.I. was chosen for the main CODES 
trial and therefore for this study due to its ease of use and previously 
documented validity in comparison studies with more elaborate diag-
nostic instruments [27]. In view of our aim to collect a considerable 
amount of outcome data, we were keen to minimise the assessment load 
for study participants as much as possible. Although all patients were 
also assessed by psychiatrists, this assessment was not on the same 
occasion as the completion of M.I.N.I. and PHQ-9. Furthermore, the trial 
protocol for this pragmatic trial did not require psychiatrists to complete 
a structured diagnostic assessment. 
The PHQ-9 [14] has been widely used to screen for major depression 
and grade depressive symptom severity. It includes questions about each 
of the nine DSM-IV criteria for depression: anhedonia, low mood, fa-
tigue, poor appetite, poor concentration, low self-esteem, hyper or 
hypoactive behaviours, sleep disturbances and suicidality. Responses 
range from 0 (not at all) to 3 (nearly every day), with total scores ≥10 
typically taken to indicate clinical depression. The PHQ-9 is perceived as 
reliable, with good sensitivity and specificity across a range of medical 
settings and populations [28], including patients with epilepsy [20,29]. 
It has been shown to have good construct validity and can be useful as a 
categorical or continuous measure of depression severity [14,30,31]. 
While there is evidence that the PHQ-2 (comprising only the two first 
items of PHQ-9) could be of similar value as the PHQ-9 as a screening 
tool for depression [32], we chose the PHQ-9 for this study because it is a 
more widely used instrument, captures a broader range of (potentially 
relevant) symptoms and contains item 9 which is appreciated by some 
services as an independent “risk” item (“Thoughts that you would be 
better off dead, or hurting yourself”). 
The Generalised Anxiety Disorder Assessment–7 (GAD-7) [33] is a 
reliable and valid seven-item scale that can be used as a screening tool 
and severity measure for generalised anxiety disorder. 
The Clinical Outcomes in Routine Evaluation–10 (CORE-10) [34] is a 
10-item scale used to measure psychological distress and screen for 
mental illness. It has high internal reliability and validity [34]. 
A modified version of the Patient Health Questionnaire–15 (PHQ-15) 
[35] was used to identify somatic symptoms. This modification com-
prises 15 items referring to common somatic symptoms (excluding 
upper respiratory infections), 10 relating to neurological symptoms [36] 
and five referring to psychological symptoms derived from the Prime 
MD Questionnaire [37]. This is a dichotomous version that asked pa-
tients if they were ‘bothered a lot’ by each of the symptoms over the past 
month (0 = No, 1 = Yes). 
The Beliefs About Emotions Scale (BES) [38] was used to measure 
beliefs about the unacceptability of experiencing or expressing negative 
emotions. The scale has good validity and internal consistency [38]. 
The Work and Social Adjustment Scale (WSAS) [39] assesses the 
ability to perform day-to-day tasks including work, home management, 
relationship interaction, and social and private leisure activities. High 
validity and test-retest reliability have been reported for the WSAS [39]. 
The Short Form 12-item Health Survey – version 2 (SF-12v2) [40] is a 
widely-used measure of health-related quality of life (HRQoL). It com-
prises eight subscales assessing mental and physical health domains and 
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gives rise to two summary scores: The Mental Component Summary 
(MCS) and Physical Component Summary (PCS). The SF-12v2 has good 
reliability and validity in measuring health status [41]. 
The European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) [42] 
also measures HRQoL. It includes five dimensions (mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression), each with 
five response levels ranging from no problems to extreme problems, and 
a visual analogue scale (EQ-5D-5L VAS). The EQ-5D-5L has adequate 
test-retest reliability and convergent / construct validity [42–44]. 
2.3. Statistical analyses 
Before tackling the primary aim of this study, we explored the factor 
structure of the PHQ-9 in our DS population: to this end, the sample was 
randomly divided in two halves for exploratory and confirmatory factor 
analyses (EFA and CFA). In both cases, item factor analysis for cate-
gorical data was used, using the weighted least squares estimator 
(WLSMV [45]). Both split-half samples were sufficiently large (N = 169 
and N = 199) for factor analyses since they captured over 100 responses 
with Ns 18 or 22 times greater than the number of items [46]. 
Measures of fit that are reported include: relative chi-square (relative 
χ2: values close to 2 suggest close fit [47]), Root Mean Square Error of 
Approximation (RMSEA - values below 0.06 indicate close fit [48]), 
Comparative Fit Index (CFI: values above 0.95 indicate a close fit; [49]), 
Taylor-Lewis Index (TLI: values above 0.95 are required for close fit 
[48]), and Standardized Root Mean Residual (SRMR: values below 0.08 
suggest a good fit [48]). Analyses were conducted in MPLUS [50]. 
The factor number in the EFA was explored using the Guttman-Kaiser 
criterion [51,52], parallel analysis [53] for categorical data using R 
package ‘random.polychor.pa’ for categorical data [54], a Cattell’s scree 
plot [55] and goodness of fit indices. 
In the CFA sample we fitted the unidimensional model, a two-factor 
model suggested by EFA and a bifactor model combining the two. 
Following the procedure described [56] we fitted a bifactor model to 
resolve the dimensionality problem in our data. A multiple indicators- 
multiple causes model (MIMIC; [57]) was fitted to the complete data 
to explore potential measurement non-invariance (biased measure-
ments) with respect to age and gender (one adjusting for the other). 
In order to address the primary aim of our study, the diagnostic ac-
curacy of the PHQ-9 total score was assessed against Current Major 
Depressive Disorder diagnoses from the M.I.N.I. 
The area under the receiver operating characteristics (ROC) curve 
(AUC) [58] was used to test the performance of the PHQ-9 at various cut- 
off points using Stata V16.0 (Stata, Texas). 
There are many ways to determine optimal cut-off points. To help 
balance sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV we calculated the following summary 
statistics: PROC01, the distance between the point on the ROC curve and 
(0,1) that should be minimised; Youden index (sensitivity + specificity – 
1), which should be as close to 1 as possible; and the diagnostic odds 
ratio (DOR), which should be maximised as it indicates the predictive 
performance of the PHQ-9 cut-off point. More specifically, the DOR 
calculates the odds of a patient categorised as ‘depressed’ in the M.I.N.I. 
as being classed ‘depressed’ on the PHQ-9, compared to a patient not 
found depressed. 
Reliability of the PHQ-9 was assessed using Cronbach’s alpha [59] 
and item-total correlations. Concurrent (convergent or discriminant) 




Table 1 shows basic demographic information for our sample. 
Further information can be found elsewhere [22]. 
Table 2 presents scores on measures of psychological distress and 
somatic symptoms (PHQ-9, GAD-7, CORE-10, Modified PHQ-15), Beliefs 
about Emotions, psychosocial functioning (WSAS) and health-related 
quality of life (SF-12v2 and EQ-5D-5L VAS). Further classifications of 
responses on the EQ-5D-5L are summarised in Supplementary Material 
2. 
3.2. Dimensionality and internal consistency 
Parallel analysis indicated that the 1-factor solution was suitable for 
Table 1 
Baseline clinical and demographic characteristics of the study sample.    
n (%)a 
(Overall N = 368) 
Age (years) Mean (SD)b 37.5 (14.3) 
Median (IQR)c [range] 35 (25, 48) [18, 78] 
Age at first dissociative seizure (years)  n = 365 
Mean (SD) 30.9 (14.1) 
Median (IQR) [range] 29 (19, 42) [1, 76] 
Duration of dissociative seizures disorder (years)  n = 365 
Mean (SD) 6.2 (8.8) 
Median (IQR) [range] 3 (1, 8) [0, 65] 
Gender Male 102 (27.7) 
Female 266 (72.3) 
Ethnicity White 330 (89.7) 
Mixed 17 (4.6) 
Black 6 (1.6) 
Asian 6 (1.6) 
Other 9 (2.4) 
Dissociative seizures diagnosed by video-EEGd Yes 195 (53.0) 
Any previous DSM-IVe diagnoses from M.I.N.I. f Yes (≥1) 247 (67.1) 
Any current DSM-IV diagnoses from M.I.N.I. Yes (≥1) 255 (69.3) 
Past diagnosis of Major Depressive Disorder from M.I.N.I. Yes 193 (52.4) 
Current diagnosis of Major Depressive Disorder from M.I.N.I. Yes 114 (31.0)  
a n = available sample size: where n < 368 this is due to missing data. 
b SD = standard deviation. 
c IQR = inter-quartile range. 
d EEG = electroencephalogram. 
e DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. 
f M.I.N.I. = Mini - International Neuropsychiatric Interview. 
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our data (see scree plot in Supplementary Material 3). One eigenvalue 
was larger than 1 (5.22), but the second was also close to 1 (0.96). 
Therefore, we fitted both the 1- and the 2-factor models. As presented in 
Table 3, a closer fit was achieved for the 2-factor model, but the fit of the 
1-factor model was adequate. These results were replicated in CFA 
where both models fitted well. 
However, as presented in Table 4, the item loadings on the uni-factor 
model were similar to the loadings of the items on the general factor of 
the bi-factor model. According to Reise et al. [56], this indicates that 
there is no loss of information if a 1-factor model is applied. Secondly, 
the loadings of the items on the general factor of the bi-factor model 
were substantially larger than their loadings on the specific factors they 
were assigned to. According to Reise et al. [56] this indicates that spe-
cific factors reflected a general trait. Finally, the loadings of the items on 
their designated factors in the two-factor CFA model (where there was 
no general factor) were much larger than their loadings to their desig-
nated factors in the bifactor model (where there was a general factor). 
These results suggest that the general factor is the prominent factor and 
the specific factors essentially reflect the general factor. The PHQ-9 
therefore emerges as a univariate tool in patients with DS. 
Two significant direct effects were identified, namely the direct ef-
fect of age on item 7 (d.e. = 0.013, p < 0.001) and the direct effect of 
gender on item 5 (d.e. = 0.3, p = 0.026). As only one item per covariate 
was found non-invariant, with small effect sizes, we conclude that PHQ- 
9 is measurement invariant with respect to gender or age. 
The internal consistency of the PHQ-9 was satisfactory (α = 0.87), 
with no increase in alpha if any of the items were deleted and satisfac-
tory individual item-total correlations ranging between 0.44 and 0.70. 
3.3. Diagnostic accuracy 
Using Current Major Depressive Disorder from the M.I.N.I. as the 
gold-standard, the overall area under the ROC curve (AUC) of the PHQ-9 
in our sample was 0.80 (Fig. 1). 
Table 5 indicates that, in our sample, using a PHQ-9 cut-off of ≥10 
for detecting depression cases has the best predictive performance; i.e. 
depressed patients have the greatest odds (DOR = 14.7) of a positive 
result compared to non-depressed patients. This is consistent with the 
current clinical cut-off. However, this cut-off achieves high sensitivity at 
the cost of low specificity, whereby only half of the individuals above 
this threshold will have clinical depression. 
Using the AUC, a more overall measure, a cut-off of ≥13 has the best 
performance, with an AUC of 0.74 and a Youden index of 0.48. This may 
be considered an optimal balance of sensitivity and specificity. The 
distance between the point on ROC curve and (0,1) is also better 
(smaller) if ≥13 is used as the cut-off compared to ≥10 (0.24 vs. 0.30), as 
well as the percentage of agreement (71.4% vs. 62.9%). 
3.4. Clinical correlates 
Table 6 shows evidence of convergent validity reflected by high 
correlations with the GAD-7 (0.779), CORE-10 (0.795) and the MCS 
score of the SF12v2 (− 0.711). Discriminant validity is indicated by 
moderate to low correlations with Beliefs about Emotions, psychosocial 
functioning, health-related quality of life and the PCS score of the SF- 
12v2. 
4. Discussion 
4.1. Brief summary of diagnostic accuracy findings 
To our knowledge, this is the first study assessing the validity of the 
PHQ-9 for depression-screening in adults with DS, comparing it to the M. 
I.N.I, a structured diagnostic tool. In our sample of DS patients, the PHQ- 
9 had very good internal consistency (Cronbach’s α = 0.87) and area 
under the curve (AUC = 0.80) values indicating high overall diagnostic 
accuracy. While the PHQ-9 should never, in isolation, be used as a 
diagnostic tool for clinical depression, these findings (and our confir-
mation of the questionnaire as a univariate instrument) suggest that it is 
a useful screening method for depressive symptoms allowing users to 
describe the likelihood of a diagnosis of clinical depression at particular 
cut-off scores. The ‘optimal’ PHQ-9 cut-off is likely to be highly 
dependent on the intention of a particular use. If employed as a clinical 
screening tool to identify depressed patients, a lower cut-off would 
ensure that no cases are missed, although expert assessments would 
reveal that many patients scoring above this threshold are not 
depressed. If used in research with the aim of selecting patients highly 
likely to be suffering from comorbid major depression, a higher cut-off 
Table 2 
Descriptive statistics for currently considered measures (maximum N = 368).  
Measure na Mean (SD)b 
[range] 
PHQ-9c (depression) (min-max 0–27) 
(Scores ≥10 typically taken to indicate clinical 
depression) 
367 12.4 (6.6) [0, 
27]  
GAD-7d (anxiety) (min-max 0–21) 
(≥5 = mild, ≥10 = moderate, ≥15 = severe) 
368 9.8 (6.2) [0,21]  
CORE-10e (distress) (min-max 0–40) 
(≥11 = clinical distress) 
368 18.2 (6.5) [4, 
34]  
Modified PHQ-15f (somatic symptoms) (min-max 0–30) 
(Higher scores reflect more symptoms) 
364 16.7 (6.5) 
[2,30]  
Beliefs about Emotions 
(min-max 0–72) 
(Higher scores reflect stronger beliefs about the 
unacceptability of experiencing and expressing 
negative emotions) 
367 41.9 (16.9) [0, 
72]  
WSASg (Impact of DS on functioning) (min-max 0–40) 
(<10 subclinical, 10–20 significant impairment but 
less severe symptomatology, >20 moderate, severe or 
worse psychopathology) 
366 22.7 (10.5) [0, 
40]  
SF-12v2h Mental Component Summary score (0 = worst 
health 100 = best health) 
366 37.8 (11.8) 
[13.4, 68.1]  
SF-12v2h Physical Component Summary score (0 = worst 
health 100 = best health) 
366 39.7 (12.2) 
[13.4, 65.9]  
EQ-5D-5L VASi (Health today) (0 = worst health 100 =
best health) 
363 55.5 (23.0) 
[1,100]  
a n = available sample size. 
b SD = standard deviation. 
c PHQ-9 = Patient Health Questionnaire-9. 
d GAD-7 = Generalised Anxiety Disorder Assessment-7. 
e CORE-10 = Clinical Outcomes in Routine Evaluation-10. 
f PHQ-15 = Patient Health Questionnaire-15. 
g WSAS = Work and Social Adjustment Scale. 
h SF-12v2 = Short Form 12-item Health Survey - version 2. 
i EQ-5D-5L VAS European Quality of Life-5 Dimensions-5 Levels Visual 
Analogue Scale. 
Table 3 
Goodness of fit indices per item factor analysis model.  
Model rel χ2 RMSEAc (95% CI) TLId CFIe SRMRf 
EFAa-1 factor 2.96 0.108 (0.081,0.136) 0.967 0.956 0.077 
EFAa-2 factor 1.51 0.055 (0.000,0.094) 0.994 0.988 0.042 
CFAb-1 factor 5.20 0.145 (0.122,0.169) 0.938 0.918 0.07 
CFAb-2 factor 2.67 0.092 (0.066,0.118) 0.976 0.967 0.047 
Bifactor model 1.45 0.035 (0.000,0.062) 0.998 0.995 0.018  
a EFA: exploratory factor analysis. 
b CFA confirmatory factor analysis. 
c RMSEA Root Mean Square Error of Approximation. 
d TLI Tucker-Lewis Index. 
e CFI Comparative fit index. 
f SRMR Standardized Root Mean Residual. 
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would be appropriate. 
With this proviso, the present study found that using a PHQ-9 cut-off 
of ≥10 for detecting depression cases had the best predictive perfor-
mance in terms of the diagnostic odds ratio (DOR = 14.7). This is 
consistent with the widely-used clinical cut-off [14]. However, a cut-off 
of ≥10 favoured sensitivity over specificity and greatly overestimated 
the presence of major depression. Using the AUC (a more global mea-
sure), we found that a cut-off of ≥13 had the best performance, with an 
AUC of 0.74 and a Youden index of 0.48, and provided an optimal 
balance of sensitivity (0.81) and specificity (0.67). At this score, over 
two-thirds of individuals with DS could be expected to have current 
major depression. However users will need to be aware that, at this cut 
off, one in five individuals with major depression is likely to be missed 
and one in three of those identified as depressed may not be found to be 
so on further examination. Nevertheless, the specificity of the instru-
ment at a cut-off of ≥13 compares favourably with the poor specificity 
value of 0.49 at the ‘standard’ cut-off score of ≥10. They should also be 
aware that the PHQ-9 identifies depressive symptoms, as indeed does 
the M.I.N.I. when used as per our protocol, rather than specifically 
diagnosing major depressive disorder. We would not, for example, 
suggest commencing pharmacotherapy on this basis but one might 
suggest that these tools have a role to play in triaging referral to an 
appropriate clinician. 
4.2. Findings in the context of previous literature 
Although this study benefitted from a large sample size, it must be 
acknowledged that participants were captured at a particular time in 
their illness journey and may not have been typical of the DS population 
at large. Given that sensitivity and specificity will very depend very 
much on the prevalence of an observation, it is therefore important to 
note that, in terms of the distribution of PHQ-9 scores [5], but also in 
terms of age and gender distribution, comorbidity and social profile, our 
findings are consistent with those among other unselected DS cohorts 
[3,6]. Our findings show that a cut-off score of ≥10 overestimates 
depression diagnoses in patients with DS even more than in other 
medical conditions [16]. To match the level of specificity of the PHQ-9 
in patients with other medical conditions at a cut-off of ≥13, as indicated 
by Levis et al., [16], we would need a cut-of score of ≥20 in our dataset. 
Similar findings by the same authors [17] suggested that a higher cut-off 
score of ≥14 estimated prevalence closest to SCID-based diagnoses, and 
thus was the most accurate depression estimate. 
A possible explanation for the much higher cut-offs needed to ach-
ieve high specificity of the PHQ-9 in our DS sample may be due to 
physical symptom confounding. The high scores on the somatic symp-
tom scale (Modified PHQ-15) and the high level of disabilities reported 
on the PCS score by patients in our study are in keeping with evidence 
from other large studies of patients with DS demonstrating the high level 
of physical comorbidities and medication use in this patient group [60]. 
It is likely that patients diagnosed with DS who have physical comor-
bidity will need higher cut-off scores compared to patients screened for 
depression without such comorbidity. Notably, the symptoms addressed 
in the PHQ-9 (anhedonia, low mood, sleeping difficulties, tiredness, lack 
of appetite, low self-esteem, poor concentration and moving slowly or 
being fidgety) can be associated with physical comorbidity, disability or 
medication [61–63]. Support for this comes from previous findings 
indicating strong correlations between depression scores and somatic 
symptoms even where a different version of the PHQ-15 from that used 
here was employed and in different populations [64,65]. Indeed, we 
previously indicated [22] that our sample of DS patients most commonly 
Table 4 
Item factor analysis loadings per model.   
EFAa (N = 168) CFAb (N = 199) 
1-factor model Uni-factor 1-factor model Uni-factor Bifactor model General factor 
Item 1 0.83 Item 1 0.71 Item 1 0.71 
Item 2 0.82 Item 2 0.85 Item 2 0.65 
Item 3 0.70 Item 3 0.76 Item 3 0.78 
Item 4 0.75 Item 4 0.76 Item 4 0.80 
Item 5 0.71 Item 5 0.65 Item 5 0.71 
Item 6 0.86 Item 6 0.83 Item 6 0.69 
Item 7 0.66 Item 7 0.69 Item 7 0.71 
Item 8 0.66 Item 8 0.66 Item 8 0.73 
Item 9 0.63 Item 9 0.72 Item 9 0.46  
2-factors model factor 1 2-factors model factor 1 specific factor 1 
Item 3 0.87 Item 3 0.80 Item 3 0.20 
Item 4 0.80 Item 4 0.80 Item 4 0.25 
Item 5 0.49 (0.31)c Item 5 0.69 Item 5 0.00 
Item 7 0.52 Item 7 0.73 Item 7 − 0.13 
Item 8 0.42 (0.31)c Item 8 0.68 Item 8 − 0.53  
factor 2 factor 2 specific factor 2 
Item 1 0.52 (0.4)c Item 1 0.73 Item 1 0.31 
Item 2 0.94 Item 2 0.87 Item 2 0.61 
Item 6 0.80 Item 6 0.85 Item 6 0.52 
Item 9 0.71 Item 9 0.72 Item 9 0.59  
a EFA = exploratory factor analysis. 
b CFA = confirmatory factor analysis. 
c Cross loadings within parentheses. 
Fig. 1. Receiver Operating Characteristics (ROC) curve.  
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reported the following co-morbid symptoms on the Modified PHQ-15: 
tiredness and low energy, headaches, sleeping difficulties, memory 
and concentration problems, worry, pain in the extremities, dizziness, 
anxiety, depression in addition to other symptoms. Other factors, 
including stigmatisation of mental health complaints and response bias, 
appear prevalent in the DS population [5,11,12] and may explain the 
low combined sensitivity and specificity of the PHQ-9 in our sample 
compared to other medical conditions [16]. Indeed, discrepancies be-
tween self-report and clinically assessed depression have been previ-
ously reported in the DS population [5]. This may be due to DS patients 
having difficulty accepting the psychological nature of their diagnosis 
and disclosing negative emotions [11,12]. To a degree, emotional dys-
regulation and high levels of alexithymia, commonly reported in DS 
[66], may also compromise the sensitivity of self-report measures. 
4.3. Implications of clinical correlates with the PHQ-9 
Intercorrelations between the PHQ-9 and other baseline measures 
provided good evidence of construct validity when considering its use in 
patients with DS; high correlations were found between PHQ-9 and the 
GAD-7 and CORE-10 measures (0.779, 0.795 respectively) and with the 
MCS score of the SF-12v2 (− 0.711). Of relevance here of course is the 
observation of wide overlap between depression, anxiety and somatic 
symptoms more generally in the population [61]. Discriminant validity 
was indicated by lower correlations between the PHQ-9 and Beliefs in 
Emotions, WSAS, EQ-5D-5L VAS, and the PCS score of the SF-12v2. 
4.4. Factor structure 
Factor analysis showed that for this population the PHQ-9 scale is 
unidimensional. To date, studies assessing the factor structure of the 
PHQ-9 yield inconclusive findings. While some studies have reported a 
two-factor structure [67] and found greater diagnostic accuracy using 
the PHQ9-CA subscale compared to the PHQ-9/S [20] (although the 
diagnostic accuracy of the PHQ9-CA was similar to the entire PHQ-9), 
several others suggest a unidimensional factor structure [68–70]. 
Since we have found one main factor, our results do not support 
considering a differential role of the cognitive/affective (PHQ-9/CA), 
and somatic (PHQ-9/S) subscales in diagnosing depression in this 
population. 
4.5. Implications of a higher cut-off score 
More generally, higher cut-offs ranging from 13 to 15 have been 
previously reported as ‘optimal’ across a range of conditions 
[17,20,67,71,72]. With respect to DS, the use of higher PHQ-9 cut-off 
scores may help reduce the overestimation of depression diagnoses in DS 
[5]. Determining the optimal diagnostic accuracy of the PHQ-9 will have 
important implications for depression screening in primary care ser-
vices, which in turn, will influence management and treatment out-
comes. Nonetheless, whether raising the PHQ-9 cut-off score to ≥13 will 
maximise accurate screening and mental health outcomes and minimise 
resource costs and adverse events compared to the traditional cut-off at 
≥10 remains unclear. 
4.6. Strengths and limitations 
Our sample, derived from a high number of participating centres, 
allowed a detailed study of the validity of the PHQ-9 in a large, well- 
characterised cohort. We also used a cut-off score approach for the 
PHQ-9, which has been recently shown to be better than alternative 
methods, such as algorithms, at detecting clinical depression [73]. 
However, potential limitations of this study also need to be considered. 
Our eligibility criteria may have led to the exclusion of people with more 
marked psychopathology along with those who did not want to be 
randomised. Additionally, we validated self-report measures against the 
M.I.N.I. and these self-report measures can be susceptible to response 
bias. While the M.I.N.I. is a well-validated instrument for the diagnosis 
of depression which has been widely used to validate self-report mea-
sures, structured or semi-structures diagnostic instruments administered 
by experienced psychiatrists may have produced different results; 
however, the costs of doing so may have impacted on sample sizes [74]. 
For instance, previous studies indicate that, compared to the SCID, the 
M.I.N.I. may also overestimate the number of participants having clin-
ical depression across a range of conditions [75,76], which might 
require the use of an even higher PHQ-9 cut-off score. 
When interpreting our study, it is important to be aware that the 
PHQ-9 and the M.I.N.I. measure somewhat different constructs of 
depression. The PHQ-9 is a continuous measure of depressive symp-
tomatology for which scores are given suggesting likelihood of a 
depressive disorder and consequent treatment implications. The M.I.N.I. 
by contrast offers a categorical definition of major depressive disorder. 
This is somewhat akin to measuring or reporting on blood pressure by 
Table 5 
Diagnostic accuracy of the PHQ-9 for Current Major Depressive Disorder (from the M.I.N.I.)  
PHQ-9 score Sensitivity Specificity PPVa NPVb % agree LR + c LR-d PROC01e Youden indexf DORg AUCh 
8 0.947 0.364 0.402 0.939 54.5 1.489 0.145 0.361 0.311 10.288 0.656 
9 0.939 0.439 0.430 0.941 59.4 1.672 0.140 0.328 0.378 11.945 0.689 
10 0.939 0.490 0.453 0.947 62.9 1.841 0.125 0.302 0.429 14.691 0.714 
11 0.912 0.561 0.484 0.934 67.0 2.079 0.156 0.271 0.473 13.303 0.737 
12 0.851 0.621 0.503 0.902 69.2 2.242 0.240 0.257 0.472 9.332 0.736 
13 0.807 0.672 0.526 0.885 71.4 2.460 0.287 0.238 0.479 8.565 0.740 
14 0.772 0.704 0.540 0.873 72.5 2.604 0.324 0.228 0.476 8.032 0.738 
15 0.711 0.735 0.547 0.849 72.8 2.683 0.394 0.228 0.446 6.815 0.723 
16 0.684 0.767 0.569 0.844 74.1 2.934 0.412 0.210 0.451 7.125 0.726 
17 0.579 0.810 0.579 0.81 73.8 3.052 0.520 0.213 0.389 5.873 0.695 
18 0.509 0.862 0.624 0.796 75.2 3.678 0.570 0.183 0.371 6.451 0.685 
19 0.421 0.885 0.623 0.772 74.1 3.673 0.654 0.194 0.306 5.618 0.653 
20 0.368 0.917 0.667 0.763 74.7 4.439 0.689 0.167 0.285 6.445 0.643  
a Positive predictive value. 
b Negative predictive value. 
c Positive likelihood ratio. 
d Negative likelihood ratio. 
e Distance between optimal point on ROC curve and (0,1). 
f Sensitivity + Specificity – 1. 
g Diagnostic odds ratio. 
h Area under the curve. 




Correlation matrix between PHQ-9 and other clinical measures.   






















j health today 
PHQ-9 –              
GAD-7 *0.779 –             
CORE-10 *0.795 *0.791 –            
Modified PHQ-15 *0.715 *0.604 *0.616 –           
Belief about 
Emotions 
*0.428 *0.454 *0.421 *0.353 –          
WSAS *0.485 *0.306 *0.367 *0.482 **0.147 –         
SF-12v2 PCS *− 0.330 **− 0.103 **− 0.148 *− 0.424 − 0.043 *− 0.515 –        
SF-12v2 MCS *− 0.711 *− 0.712 *− 0.694 *− 0.575 *− 0.381 *− 0.339 − 0.075 –       
EQ-5D-5L 
mobility 
*0.321 **0.141 *0.197 *0.375 0.093 *0.456 *− 0.689 − 0.070 –      
EQ-5D-5L self- 
care 
*0.411 *0.245 *0.264 *0.444 **0.152 *0.507 *− 0.609 *− 0.219 *0.664 –     
EQ-5D-5L usual 
activities 
*0.459 *0.300 *0.313 *0.424 *0.179 *0.529 *− 0.609 *− 0.230 *0.591 *0.668 –    




*0.669 *0.675 *0.679 *0.540 *0.351 *0.365 *− 0.206 *− 0.635 *0.279 *0.308 *0.424 *0.352 –  
EQ-5D-5L VAS 
health today 
*− 0.563 *− 0.398 *− 0.454 *− 0.509 *− 0.213 *− 0.460 *0.551 *0.352 *− 0.469 *− 0.455 *− 0.536 *− 0.534 *− 0.478 –  
* Significant at p < 0.001. 
** Significant at p < 0.05. 
a PHQ-9 = Patient Health Questionnaire-9. 
b GAD-7 = Generalised Anxiety Disorder Assessment-7. 
c CORE-10 = Clinical Outcomes in Routine Evaluation-10. 
d Mod PHQ-15 = Modified Patient Health Questionnaire-15. 
e WSAS = Work and Social Adjustment Scale. 
f SF-12v2 = Short Form 12-item Health Survey - version 2. 
g PCS = Physical Component Summary. 
h MCS = Mental Component Summary. 
i EQ-5D-5L European Quality of Life-5 Dimensions-5 Levels. 
j VAS = Visual Analogue Scale. 
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systolic/diastolic values or reporting a group of patients as suffering 
hypertension. There are advantages and disadvantages to both con-
structs. Kroenke and colleagues [14] in their original validation paper 
found some problems with mapping one construct onto the other and 
found a trade-off between sensitivity and specificity when mapping 
PHQ-9 scores to categorical diagnoses. Importantly, a recent meta- 
analysis demonstrated that both of these modes of assessment only 
showed low to moderate correlations with clinical mental health diag-
nosis (including depression) based on the assessment of an experienced 
clinician capable of taking account of a much wider range of personal 
and contextual circumstances [77]. 
In conclusion, our findings are not inconsistent with other PHQ-9 
validation studies suggesting generalisability of our results and that 
use of the PHQ-9 in assessing depression in patients with DS should be 
considered, albeit with a higher than normally recommended cut-off 
score. While the PHQ-9 can be an effective screening instrument in 
patients with DS, a diagnosis of depression must involve assessment by 
an appropriately trained clinician. 
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